Try our beta test site
189 studies found for:    "Peripheral T-cell lymphoma"
Show Display Options
Rank Status Study
1 Not yet recruiting Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients
Condition: Peripheral T Cell Lymphoma
Interventions: Drug: chidamide;   Drug: cyclophosphamide;   Drug: liposomal doxorubicin;   Drug: vincristine;   Drug: prednisone
2 Recruiting Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study
Condition: Peripheral T-cell Lymphomas
Interventions: Drug: GDP;   Biological: Endostar
3 Completed
Has Results
Treatment of Peripheral T-cell Lymphoma
Condition: Peripheral T-cell Lymphoma
Interventions: Drug: GDPT regimen;   Drug: CHOP regimen
4 Completed CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma
Condition: Peripheral T-Cell Lymphoma
Intervention: Drug: Alemtuzumab
5 Unknown  Study of Bortezomib Combined With ACVBP in Peripheral T-Cell Lymphoma
Condition: Peripheral T-Cell Lymphoma
Intervention: Drug: Velcade + ACVBP regimen
6 Active, not recruiting
Has Results
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
Condition: Peripheral T-cell Lymphoma
Intervention: Drug: Romidepsin
7 Completed Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)
Condition: Peripheral T-Cell Lymphoma
Intervention: Biological: KW-0761 (mogamulizumab)
8 Not yet recruiting Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients
Condition: Peripheral T-cell Lymphoma
Interventions: Drug: Chidamide;   Drug: cyclophosphamide;   Drug: adriacin;   Drug: vincristine;   Drug: prednisone
9 Terminated
Has Results
Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30
Condition: Peripheral T-Cell Lymphoma
Intervention: Drug: Brentuximab vedotin
10 Completed Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
Condition: Peripheral T-cell Lymphoma
Intervention: Drug: PXD101
11 Completed
Has Results
Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Condition: Peripheral T-cell Lymphoma
Intervention: Drug: Pralatrexate Injection
12 Recruiting Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma
Condition: Peripheral T Cell Lymphoma
Intervention: Drug: Chidamide
13 Completed E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma
Condition: Peripheral T-Cell Lymphoma
Intervention: Biological: denileukin diftitox (E7777)
14 Active, not recruiting Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Condition: Peripheral T-cell Lymphoma
Intervention:
15 Not yet recruiting Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma
Condition: Peripheral T Cell Lymphoma
Intervention: Drug: Chidamide with ICE regimen
16 Recruiting Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma
Condition: Peripheral T Cell Lymphoma
Intervention: Drug: Chidamide
17 Completed Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas
Condition: Peripheral T-cell Lymphomas
Intervention: Drug: Alemtuzumab (Campath-1H)
18 Completed A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL)
Condition: Peripheral T-cell Lymphoma
Intervention: Drug: SP-02L (darinaparsin for injection)
19 Active, not recruiting Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Condition: Peripheral T-cell Lymphoma
Interventions: Drug: Pralatrexate injection;   Dietary Supplement: Vitamin B12;   Dietary Supplement: Folic Acid
20 Recruiting A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Condition: Peripheral T-Cell Lymphoma
Intervention: Drug: SP-02L (darinaparsin for injection)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.